Shares of Vivus, Inc. ( VVUS - Get Report) declined by nearly 4% today after performing well the last couple of days based on a regulatory filing with the Securities and Exchange Commission. The filing indicated that an investment firm called Aspen Investment Fund LLC may make an offer to buy out the drug maker. However, there could be something fishy going on here, making this situation worth a second or third look by investors. This isn’t to say that something’s definitely wrong here. This entire situation could be entirely legitimate and Aspen might really be thinking about making an offer for Vivus, Inc. ( VVUS - Get Report). But there are causes for concern, with the big one being that the firm that said it might make an offer doesn’t appear to even be in U.S. regulatory databases.
More from Stocks
This Is How Much Room Gold and Stocks Have Left Before a Correction
This trader called the summer gold rally, now he is eyeing these price levels.
WeWork's CEO Dumped a Lot of Stock Ahead of its IPO. Red Flag?
WeWork was valued at $47 billion earlier this year, but its heavy losses have also raised eyebrows in the run-up to its expected IPO.
Microsoft, JCI and the UAE: The Internet of Things Blossoms in the Desert
Big glass box buildings have become common across the world's cityscapes. But they can be energy gluttons. Enter Microsoft and Johnson Controls for IoT software, switches and controls in a venture with a UAE recycling and waste-management company.